Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ADCT NASDAQ:FHTX NASDAQ:PYXS NASDAQ:RCKT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADCTADC Therapeutics$3.16+10.1%$2.59$1.05▼$4.13$284.64M1.89596,760 shs860,980 shsFHTXFoghorn Therapeutics$5.51+12.7%$4.48$2.94▼$10.25$272.58M3.05142,448 shs111,089 shsPYXSPyxis Oncology$1.17+3.5%$1.19$0.83▼$5.39$70M1.13732,856 shs351,139 shsRCKTRocket Pharmaceuticals$3.20+8.1%$4.24$2.19▼$26.98$316.08M0.672.23 million shs4.34 million shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADCTADC Therapeutics+10.49%+12.06%-11.48%+180.89%-0.32%FHTXFoghorn Therapeutics+12.68%+11.31%+20.04%+70.59%+12.91%PYXSPyxis Oncology+3.54%-2.50%-13.33%+28.95%-58.66%RCKTRocket Pharmaceuticals+8.11%+11.11%+5.96%-35.22%-84.87%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADCTADC Therapeutics1.5247 of 5 stars3.52.00.00.00.00.80.6FHTXFoghorn Therapeutics1.2916 of 5 stars3.60.00.00.00.01.70.6PYXSPyxis Oncology1.6695 of 5 stars3.41.00.00.01.80.80.6RCKTRocket Pharmaceuticals4.8465 of 5 stars4.22.00.04.71.75.01.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADCTADC Therapeutics 3.00Buy$7.75145.25% UpsideFHTXFoghorn Therapeutics 3.13Buy$12.13120.05% UpsidePYXSPyxis Oncology 2.80Moderate Buy$9.00669.23% UpsideRCKTRocket Pharmaceuticals 2.41Hold$18.60481.25% UpsideCurrent Analyst Ratings BreakdownLatest PYXS, RCKT, FHTX, and ADCT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/20/2025ADCTADC TherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeOutperform ➝ Moderate Buy$8.00 ➝ $5.006/17/2025RCKTRocket PharmaceuticalsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$12.00 ➝ $5.006/13/2025ADCTADC TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.00 ➝ $10.006/3/2025RCKTRocket PharmaceuticalsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$34.00 ➝ $11.005/30/2025RCKTRocket PharmaceuticalsEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ In-Line$5.005/28/2025RCKTRocket PharmaceuticalsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy5/28/2025RCKTRocket PharmaceuticalsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Neutral5/28/2025RCKTRocket PharmaceuticalsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$32.00 ➝ $9.005/28/2025RCKTRocket PharmaceuticalsBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$30.00 ➝ $8.005/28/2025RCKTRocket PharmaceuticalsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSector Outperform ➝ Sector Outperform$51.00 ➝ $19.005/28/2025RCKTRocket PharmaceuticalsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeNeutral ➝ Sell(Data available from 7/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADCTADC Therapeutics$70.84M4.42N/AN/A($2.10) per share-1.50FHTXFoghorn Therapeutics$22.60M13.59N/AN/A($0.82) per share-6.72PYXSPyxis Oncology$16.15M4.49N/AN/A$2.03 per share0.58RCKTRocket PharmaceuticalsN/AN/AN/AN/A$5.08 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADCTADC Therapeutics-$157.85M-$1.45N/AN/AN/A-197.64%N/A-45.57%8/5/2025 (Estimated)FHTXFoghorn Therapeutics-$86.62M-$1.36N/AN/AN/A-342.23%N/A-27.28%8/6/2025 (Estimated)PYXSPyxis Oncology-$77.33M-$1.59N/AN/AN/AN/A-57.49%-45.17%8/13/2025 (Estimated)RCKTRocket Pharmaceuticals-$258.75M-$2.63N/AN/AN/AN/A-64.92%-56.13%8/4/2025 (Estimated)Latest PYXS, RCKT, FHTX, and ADCT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/5/2025Q2 2025ADCTADC Therapeutics-$0.36N/AN/AN/A$17.82 millionN/A8/4/2025Q2 2025RCKTRocket Pharmaceuticals-$0.57N/AN/AN/A$4.36 millionN/A5/15/2025Q1 2025PYXSPyxis Oncology-$0.29-$0.35-$0.06-$0.35N/AN/A5/14/2025Q1 2025ADCTADC Therapeutics-$0.38-$0.36+$0.02-$0.36$17.71 million$23.03 million5/14/2025Q1 2025FHTXFoghorn Therapeutics-$0.30-$0.30N/A-$0.30$4.96 million$5.95 million5/13/2025Q1 2025RCKTRocket Pharmaceuticals-$0.58-$0.56+$0.02N/AN/AN/A5/5/2025Q1 2025RCKTRocket Pharmaceuticals-$0.59-$0.56+$0.03-$0.56$0.80 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADCTADC TherapeuticsN/AN/AN/AN/AN/AFHTXFoghorn TherapeuticsN/AN/AN/AN/AN/APYXSPyxis OncologyN/AN/AN/AN/AN/ARCKTRocket PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADCTADC TherapeuticsN/A4.464.16FHTXFoghorn TherapeuticsN/A3.163.16PYXSPyxis OncologyN/A7.757.75RCKTRocket Pharmaceuticals0.059.199.19Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADCTADC Therapeutics41.10%FHTXFoghorn Therapeutics61.55%PYXSPyxis Oncology39.09%RCKTRocket Pharmaceuticals98.39%Insider OwnershipCompanyInsider OwnershipADCTADC Therapeutics5.40%FHTXFoghorn Therapeutics7.58%PYXSPyxis Oncology10.60%RCKTRocket Pharmaceuticals24.76%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADCTADC Therapeutics31099.18 million93.82 millionOptionableFHTXFoghorn Therapeutics12055.74 million51.52 millionOptionablePYXSPyxis Oncology6061.95 million55.38 millionOptionableRCKTRocket Pharmaceuticals240106.79 million80.35 millionOptionablePYXS, RCKT, FHTX, and ADCT HeadlinesRecent News About These CompaniesNUST Rocket Team Wins “Most Dedicated Team” at UK’s Mach-25 Competition3 hours ago | techjuice.pkTROSEN, TRUSTED INVESTOR COUNSEL, Encourages Rocket Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - RCKT - StockhouseJuly 9 at 10:09 PM | stockhouse.comBerger Montague PC Investigates Rocket Pharmaceuticals (RCKT) Over Safety Disclosures and Stock DropJuly 9 at 5:16 PM | prnewswire.comRocket Pharmaceuticals, Inc. (RCKT) Faces Securities Class Action Amid Protocol Change and FDA's Clinical Hold on Gene Therapy Trial – Hagens BermanJuly 9 at 5:11 PM | globenewswire.comRocket Announce Debut Album, Hear: “Wide Awake”July 9 at 5:08 PM | pastemagazine.comPRocket CRM Announces Advanced CRM Automation System to Streamline Customer Management and Operational EfficiencyJuly 9 at 5:08 PM | freep.comF2025-07-07 | Rocket Pharmaceuticals, Inc. (RCKT) Lawsuit - Investors Urged to Contact Levi & Korsinsky Before August 11, 2025 | NDAQ:RCKT | Press Release - StockhouseJuly 8 at 8:33 PM | stockhouse.comRocket Pharmaceuticals, Inc. (RCKT) - Yahoo FinanceJuly 8 at 8:33 PM | finance.yahoo.comLevi & Korsinsky Notifies Shareholders of Rocket Pharmaceuticals, Inc.(RCKT) of a Class Action Lawsuit and an Upcoming DeadlineJuly 8 at 3:49 PM | globenewswire.comIndia Bolsters Naval Might with Extended Range Anti-Submarine Rocket SuccessJuly 8 at 3:31 PM | devdiscourse.comDIndia Boosts Naval Strength with Indigenous Anti-Submarine Rocket SuccessJuly 8 at 3:31 PM | devdiscourse.comDRocket Pharmaceuticals, Inc. (RCKT) Investors Who Lost Money Have Opportunity to Lead Securities Fraud LawsuitJuly 8 at 12:00 PM | prnewswire.comRCKT INVESTOR ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In RCKT To Contact Him Directly To Discuss Their OptionsJuly 8 at 11:20 AM | prnewswire.comRobbins Geller Rudman & Dowd LLP Files Rocket Pharmaceuticals Class Action LawsuitJuly 8 at 10:31 AM | lawyer-monthly.comLAugust 11, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against RCKTJuly 8 at 9:00 AM | prnewswire.comINVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Rocket Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit - RCKTJuly 8 at 6:00 AM | globenewswire.comRocket Pharmaceuticals (NASDAQ:RCKT) Share Price Passes Below 50 Day Moving Average - Should You Sell?July 8 at 4:56 AM | marketbeat.comRCKT Investors Have Opportunity to Lead Rocket Pharmaceuticals, Inc. Securities Fraud LawsuitJuly 7 at 9:10 PM | prnewswire.comROSEN, SKILLED INVESTOR COUNSEL, Encourages Rocket Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – RCKTJuly 7 at 7:03 PM | globenewswire.comRocket Pharmaceuticals, Inc. Sued for Securities Law Violations – Investors Should Contact The Gross Law Firm Before August 11, 2025 to Discuss Your Rights – RCKTJuly 7 at 4:47 PM | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Rocket Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - RCKTJuly 7 at 2:45 PM | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePYXS, RCKT, FHTX, and ADCT Company DescriptionsADC Therapeutics NYSE:ADCT$3.16 +0.29 (+10.10%) Closing price 07/9/2025 03:57 PM EasternExtended Trading$3.17 +0.01 (+0.19%) As of 04:01 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound, ADCT-602 that is in a Phase 1/2 investigator-initiated study in relapsed or refractory B-cell acute lymphoblastic leukemia. Further, its clinical-stage pipeline consists of ADCT-601 (mipasetamab uzoptirine) targeting AXL as a single agent and/or in combination in sarcoma, pancreatic, and NSCLC, as well as pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, and other undisclosed targets. The company was incorporated in 2011 and is headquartered in Epalinges, Switzerland.Foghorn Therapeutics NASDAQ:FHTX$5.51 +0.62 (+12.68%) Closing price 07/9/2025 04:00 PM EasternExtended Trading$5.50 0.00 (-0.09%) As of 04:06 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It develops FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM that is in phase I for the treatment of relapsed and/or refractory acute myeloid leukemia/myelodysplastic syndrome. The company is also developing therapies for mutant cancers, such as Non-Small Cell Lung, bladder, endometrial, colorectal, and melanoma cancers; and dependent cancers, including prostate cancer and diffuse large b-cell lymphoma. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.Pyxis Oncology NASDAQ:PYXS$1.17 +0.04 (+3.54%) Closing price 07/9/2025 04:00 PM EasternExtended Trading$1.16 -0.01 (-0.85%) As of 07/9/2025 07:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients who previously progressed on PD-(L)1 inhibitors, which is in Phase 2 clinical trial for the treatment of solid tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and melanoma in combination with chemotherapy, radiation therapy, and immunotherapy. It has in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates directed to certain licensed targets, including PYX-201 and PYX-203, and products containing the ADC product candidates; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.Rocket Pharmaceuticals NASDAQ:RCKT$3.20 +0.24 (+8.11%) Closing price 07/9/2025 04:00 PM EasternExtended Trading$3.21 +0.01 (+0.31%) As of 04:50 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy. It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Tesla Stock Could Accelerate on New EV Tax Legislation SoundHound Rises as Short Sellers Exit and AI Demand Grows Why Marvell Could Be the Smartest AI Bet Under $80 Autodesk Stock Ready to Rip? Q3 May Be the Turning Point Amazon's Prime Day Pullback Meets Bullish Golden Cross Signal Palantir’s Revenue Surge to $1B: Growth vs. Valuation Chime Financial: Analysts Ring In—And It’s a Buy Is Fortinet Ready to Break Out After Months of Consolidation? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.